1-3 of 3
Jian Mei
Close
Sort by
Journal Articles

Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

Firas El Chaer, James McCloskey, Lindsay A.M. Rein, Randy A. Brown, Steven D. Green, Jeffrey J. Pu, Shuichi Shirane, Kazuya Shimoda, Michiko Ichii, Junichiro Yuda, Joseph Scandura, Sujan Kabir, Jason M Foulks, Jian Mei, Huyuan Yang, Mark Wade, Carl Stapinski, Claudia Lebedinsky, Raajit K Rampal
Journal: Blood
Blood (2022) 140 (Supplement 1): 594–595.
https://doi.org/10.1182/blood-2022-159086
Published: 2022
Journal Articles

A Phase 1 Study of TP-3654, an Orally-Delivered PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis

Claudia Lebedinsky, MD, Stephen P. Anthony, DO, Golam Mohi, PhD, Huyuan Yang, PhD, Jian Mei, PharmD, Edgar Braendle, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-134039
Published: 2020
Journal Articles

Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2

Ji-yan Liu, Yu-quan Wei, Li Yang, Xia Zhao, Ling Tian, Jian-mei Hou, Ting Niu, Fen Liu, Yu Jiang, Bing Hu, Yang Wu, Jing-mei Su, Yan-yan Lou, Qiu-ming He, Yan-jun Wen, Jin-liang Yang, Bing Kan, Yong-qiu Mao, Feng Luo, Feng Peng
Journal: Blood
Blood (2003) 102 (5): 1815–1823.
https://doi.org/10.1182/blood-2002-12-3772
Published: 2003